GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Diagnamed Holdings Corp (XCNQ:DMED) » Definitions » Valuation Rank

Diagnamed Holdings (XCNQ:DMED) Valuation Rank


View and export this data going back to 2022. Start your Free Trial

What is Diagnamed Holdings Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Diagnamed Holdings Valuation Rank Related Terms

Thank you for viewing the detailed overview of Diagnamed Holdings's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Diagnamed Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Diagnamed Holdings Corp (XCNQ:DMED) » Definitions » Valuation Rank
Comparable Companies
TSXV:CHS TSXV:EKG TSXV:OKAI XCNQ:NARA TSXV:CSPN TSXV:NEWU XCNQ:TMED XCNQ:NDAT XCNQ:KETA TSXV:KOVO GEHC VEEV ASX:PME DOCS SOLV TEM HQY TSE:2413 WAY HKSE:02228
Traded in Other Exchanges
DGNMF:USA
Address
82 Richmond Street East, Toronto, ON, CAN, M5C 1P1
Website
https://www.diagnamed.com
Diagnamed Holdings Corp is engaged in developing a platform of software-based prescription digital therapeutic products (PDT Products) with the potential to improve early detection of neurological disorders, overall patient health and lower healthcare costs. Its products include, CERVAI which is a brain health AI platform leveraging that aims to predict and monitor brain age and provide actionable insights for mental health and neurodegenerative disorders. It is also investigating other technological applications such as BrainAge and BrainTremor.
Executives
Fabio Chianelli Director, Senior Officer